Despite astonishing progress concerning cardiovascular diseases, patients are still suffering from complications of acute insults. Due to reverse remodeling and improper myocyte rebuilding, heart failure has become a common problem these days which needs more powerful myocardial reconstructing strategies. Indeed, no option cases afflicted with non-healing peripheral vascular diseases; refractory stable and unstable angina is the other field with paucity of proper treatments. For these cases, stem cell-based therapies became optimistic treatment, but lack of guideline-based indications regarding stem-cell is still a major problem which limits application of these cells for such end-stage cases. Here, an outline of appropriateness criteria for stem cell-based therapy is suggested.
Introduction
Despite the astonishing progress made in interventional cardiology, cases are still suffering from complications of acute events. Conflicted cases are most often survived from acute insults but deleterious effects of negative remodeling on future outcomes of patients are devastating. Unfortunately in some instances, the vicious cycle of progressive compensatory remodeling cannot be broken by reperfusion strategies and patients ultimately manifest signs and symptoms of poor ventricular function. Thus, myocyte rebuilding and vascular rebuilding seem to be necessarily adjoined.
The field of stem cell therapy for myocardial regeneration began to expand gradually. Since now, several clinical trials of cell transplantation in the setting of acute myocardial infarction (AMI) have been performed. Various stem-cell types and delivery roots have been examined for better efficacy with the goal of perseveration of left ventricular pump function and prevention of developing heart failure. In the case of neglected cell salvage in acute setting, recovery of the failing heart is essential. Much work is needed to be done by stem-cells to re-establish dead myocytes surrounded by fibrous tissue. Stem-cells opened new horizons in the treatment of patients with heart failure irrespective of the etiology. Cellular therapeutic options are also applied for the treatment of refractory angina pectoris. As a matter of fact, stem-cells with high differentiation capacity have the potential to be used for different clinical scenarios, in which peripheral vascular diseases are not exclusion. Disorders related to vascular insufficiency as chronic non-healing wounds have been shown to be improved using cell-based approaches as well.
Despite proved efficacy and safety of cell-based interventions, lack of specific guidelines limit their broad applications especially in acute setting. Indeed, some might not be familiar with the concept of cell-based therapies for acute situations and keep this option just for chronic end-stage cases. Additionally, cellular approaches contain a broad category as pure or modified stem-cells or recruitment and mobilization of stem-cells using chemotactic agents. 1, 2 The paucity of constructed guidelines for cell-based approaches in the field of cardiovascular diseases partly backs to ethical issues. Go with guideline (GWG) approaches are not yet paid attention for cell strategies as for other stateof-art medical managements. In any case, availability of guidelines makes both physician and patients confident about the accuracy of the decisions. 3 Currently, appropriate use criteria (AUC) are generated and updated for various cardiovascular
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www.mui.ac.ir 9 Sep diagnostic and therapeutic tests under support of several professional organizations. AUC includes three categories as "appropriate" (acceptable and reasonable), "uncertain" (generally acceptable and may be reasonable) or "inappropriate" (acceptable and is not reasonable). 4 In order to shed more lights on cellular strategies, the need for development of a unified guideline is obvious. To scheme such an outline published randomized clinical trials (RCTs), non-RCTs and case series articles have been selected and their inclusive, non-inclusive and exclusive criteria have been evaluated. All criteria have been collected and this scheme was approached.
Discussion
An outline of AUC-based indications, uncertainties and contraindications of cell-based interventions for cardiovascular diseases is presented in table 1. However, it is just a scheme and its development needs a technical panel of physicians to review and score vast of clinical scenarios as how likely it would improve outcomes or survival of a patient. This proposed scheme is based on current understanding of technical capabilities and potential benefits of this treatment. Proposed panelist team to give the rate of indications should include interventional cardiologists, non-interventional cardiologists, cardiovascular surgeons, health outcomes researchers, medical officers from a health plan, basic researchers expert in the field of stem cell-based therapies and members of data and safety monitoring board (DSMB). Certainly, these shared evidence-based tips are not intended to replace clinical experience and judgment. www.mui.ac.ir Allergy to Aspirin, Clopidogrel, Heparin I Active bleeding including blood on urine dipstick or fecal occult blood I Anticipated inability to aspirate patient's bone marrow or draw enough blood volume needed for stem cell isolation and preparation I Uncontrolled arrhythmia I Constant atrial fibrillation/flutter (unless paced in a regular rhythm) I Presence of mechanical aortic or mitral prosthetic valve I Stem cell tracking U Cardiac imaging after cell delivery in a timely manner U In-vitro and in-vivo assessment of cell potency [using cell invasion and migration assays and imaging protocols as Cardiovascular magnetic resonance (CMR), respectively] U 5000-10,000 IU unfractionated heparin after sheath insertion for percutaneous cell delivery U Specific conditions (Non-ischemic cardiomyopathies) AUC category Ill children with cardiomyopathy due to anti-cancer agents A Ejection fraction (EF) less equal or less than 35% with evidence of congestive heart failure A Symptomatic patients for more than one year at New York Heart Association (NYHA III-IV) despite optimal pharmacologic therapy for more than 3 months A NYHA II have been hospitalized with a dilated cardiomyopathy related condition A At least 7% reversibility and viability showed by nuclear study A Confirmed diagnosis of non-ischemic cardiomyopathy with normal coronary angiography A Serum B-type Natriuretic Peptide (BNP) level > 100 pg/ml. Severe and persistent HF with EF < 35% and or limiting angina (classes II to IV) A Significant coronary heart disease not amenable to revascularization or ineffective coronary revascularization during last 6 months A Presence of a defect identified by nuclear imaging A History of Q-wave MI with a residual akinetic and nonviable scar A Scheduled for surgical revascularization within few days (< 2 weeks) of the initial screening A End-stage or uncontrollable congestive heart failure without continues infusion of catecholamine I Patient is scheduled for heart transplantation I Patients requiring surgical correction of LV aneurism I www.mui.ac.ir 
